Calcific aortic valve disease: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}}; {{AOEIC}} {{LG}} | ||
==Overview== | ==Overview== | ||
| Line 6: | Line 6: | ||
:*[[Aortic sclerosis]] and | :*[[Aortic sclerosis]] and | ||
:*[[Aortic stenosis]] | :*[[Aortic stenosis]] | ||
==2008 ACCP Guideline Recommendations <ref name="pmid18574274">{{cite journal |author=Salem DN, O'Gara PT, Madias C, Pauker SG |title=Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) |journal=[[Chest]] |volume=133 |issue=6 Suppl |pages=593S–629S |year=2008 |month=June |pmid=18574274 |doi=10.1378/chest.08-0724 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=18574274 |accessdate=2012-04-10}}</ref>== | |||
{{cquote| | |||
====[[ACCP guidelines classification scheme#Grading Scheme Classification|Grade 2]]==== | |||
'''1.''' In patients with isolated calcific aortic valve disease who have not had [[ischemic stroke]] or [[transient ischemic attack]], we suggest against antithrombotic therapy. ''([[ACCP guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' | |||
'''2.''' In patients with isolated calcific aortic valve disease who have had [[ischemic stroke]] or [[transient ischemic attack]] not attributable to another source, we suggest [[aspirin]] (50 to 100 mg/d). ''([[ACCP guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''}} | |||
==Guidelines Resources== | |||
*[http://chestjournal.chestpubs.org/content/133/6_suppl/593S.long#sec-1 Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)]<ref name="pmid18574274">{{cite journal |author=Salem DN, O'Gara PT, Madias C, Pauker SG |title=Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) |journal=[[Chest]] |volume=133 |issue=6 Suppl |pages=593S–629S |year=2008 |month=June |pmid=18574274 |doi=10.1378/chest.08-0724 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=18574274 |accessdate=2012-04-10}}</ref> | |||
==References== | ==References== | ||
Revision as of 20:23, 11 April 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2]
Overview
- Calcific aortic valve disease includes both:[1]
2008 ACCP Guideline Recommendations [2]
| “ |
Grade 21. In patients with isolated calcific aortic valve disease who have not had ischemic stroke or transient ischemic attack, we suggest against antithrombotic therapy. (Level of Evidence: C) 2. In patients with isolated calcific aortic valve disease who have had ischemic stroke or transient ischemic attack not attributable to another source, we suggest aspirin (50 to 100 mg/d). (Level of Evidence: C) |
” |
Guidelines Resources
- Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[2]
References
- ↑ O'Brien KD (2006). "Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more)". Arteriosclerosis, Thrombosis, and Vascular Biology. 26 (8): 1721–8. doi:10.1161/01.ATV.0000227513.13697.ac. PMID 16709942. Retrieved 2012-04-11. Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 Salem DN, O'Gara PT, Madias C, Pauker SG (2008). "Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 593S–629S. doi:10.1378/chest.08-0724. PMID 18574274. Retrieved 2012-04-10. Unknown parameter
|month=ignored (help)